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Background. The AVPR2 gene encodes the type 2 vasopressin
receptor, a member of the vasopressin/oxytocin receptor subfam-
ily of G protein-coupled receptors. Disruption of AVPR2 causes
X-linked congenital nephrogenic diabetes insipidus (NDI), yet the
functional significance of most gene sequence variations found in
association with NDI has not been proven. The large number of
naturally occurring AVPR2 mutations constitutes a model system
for studying the structure-function relationship of G protein-
coupled receptors. This analysis can be aided by examining amino
acid sequence variation and conservation among evolutionarily
disparate members of the subfamily.
Methods. Twenty-five new NDI patients were evaluated by
DNA sequencing for mutations in AVPR2. Receptors encoded by
eighteen NDI alleles were tested for physiologic signaling activity
in response to varying concentrations of arginine vasopressin
(AVP) in a sensitive cell culture assay. Seventeen amino acid
sequences from the vasopressin/oxytocin receptor subfamily were
aligned and conserved residues were identified and correlated
with the locations of NDI associated variations.
Results. Twenty-four variant alleles were found among the 25
new patients. Thirteen had no prior family history of expressed
NDI. All 18 of the NDI-associated AVPR2 alleles tested for
function demonstrated diminished response to stimulation with
AVP. Twelve failed to respond at all, whereas six signaled only at
high AVP concentrations. Evolutionarily conserved residues clus-
tered in the transmembrane domains and in the first and second
extracellular loops, and NDI-associated missense mutations ap-
peared mostly in the conserved domains.
Conclusions. Sporadic cases are frequent and they usually
represent the X-linked rather than the autosomal form of NDI.
Genetic and functional testing can confirm this in individual cases.
Mutations in this study affecting ligand binding domains tend to
retain partial signaling in vitro, whereas those that introduce a
charged residue in a transmembrane domain are inactive. The
minimal partial signaling observed in cultured cells is unlikely to
correlate with clinically significant urine concentrating ability.
Other AVPR2 mutations with milder effects on receptor function
probably exist, but may not be expressed clinically as typical NDI.
Congenital nephrogenic diabetes insipidus (NDI) is an
inborn error of water homeostasis caused by insensitivity of
the distal renal tubule and collecting duct to the effects of
the pituitary-derived hormone arginine vasopressin (AVP).
Two genetic forms of NDI are known. The more common
form results from mutations in the type 2 receptor for AVP
(V2 receptor), a G protein-coupled receptor, that inhibit its
capacity to respond to increases in serum AVP [1–5]. Since
the V2 receptor gene, AVPR2, resides in chromosome
band Xq28, this form of the disease is inherited in an
X-linked fashion. Like other X-linked disorders with his-
torically reduced probability of reproduction in the affected
males, new mutations are frequent.
In other NDI cases, a transmembrane water channel
protein, aquaporin-2, is defective [6–11]. The encoding
gene, AQP2, resides on chromosome 12, so its inheritance
is autosomal. The majority of cases thus far described have
occurred in families with known consanguinity. Proper
genetic counseling of NDI patients and their families,
especially those without an informative family history,
requires that the two forms be distinguished. Furthermore,
as the science of this disorder progresses, new treatments
aimed at one or the other form will be devised, and having
a clear picture of the abnormal biology in an individual case
will be imperative.
In addition to its clinical relevance, the study of varia-
tions that affect the function of the V2 receptor has
scientific value. When combined with other research, it may
help decypher how the receptor’s structure defines its
function, and may even provide insight into the function of
the large numbers of G protein-coupled receptors.
These receptors comprise a diverse and ancient super-
family of transmembrane signaling proteins. All couple to a
less extensive collection of heterotrimeric G proteins and
share the apparently invariable characteristic of seven
hydrophobic transmembrane domains. However, since few
amino acid residues have been completely conserved in
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evolution across the entire superfamily, comparisons of
primary amino acid sequence imply little about the funda-
mental structure-function relationship of these membrane
proteins [12]. Unfortunately, the complete tertiary struc-
ture of a member of the superfamily has not been deter-
mined experimentally.
It is possible, however, to infer functional domains based
on the abnormal behavior of receptors with modified amino
acid sequences. One aspect of this approach involves
analyzing receptors with mutations that reduce or eliminate
the ability to transduce a signal. The V2 vasopressin
receptor is unique among the mammalian G protein-
coupled receptors in that many functionally impaired ver-
sions are available from patients with NDI.
We previously reported eleven AVPR2 gene mutations
associated with NDI in humans [13]. We now report 24
additional mutations and present evidence of reduced or
eliminated function of the encoded receptors for 18 of
them. This confirms their causal relationship to the disor-
der, and sets the stage for an experimental analysis of
structure and function at the molecular level.
METHODS
Patients
Blood samples were obtained with informed consent
from patients with a clinical diagnosis of Nephrogenic
Diabetes Insipidus. All reportedly had evidence of abnor-
mally low responsiveness to injected vasopressin or desmo-
pressin (a vasopressin analogue selective for the V2 recep-
tor), or they had a history of an affected male relative with
abnormally low responsiveness.
Genomic DNA extraction
Genomic DNA was extracted from 3 to 7 ml of periph-
eral blood anticoagulated with EDTA or with ACD using
either PureGene kit (Gentra Systems, Research Triangle
Park, NC, USA) or an organic extraction protocol em-
ployed by the DNA Diagnostic Laboratory at Oregon
Health Sciences University.
Avpr2 amplification and direct sequencing
The entire AVPR2 gene was amplified using the poly-
merase chain reaction (PCR) from 125 ng of genomic DNA
using the XL-PCR kit (Applied Biosystems) and the fol-
lowing primers (59-.39) in the PTC-200 DNA Engine (MJ
Research): BW204 (TGG AAT TCG GCT TTG CTC CTC
AGG CAG AGG CTG A) and BW205 (CAG AAT TCG
GCT TAG GGA TTA GAA AGG CGG AGA CA).
The amplification parameters were: hot start at 94°C,
cycle 94°C for 30 seconds, and 66°C for five minutes, fifty
times, followed by 72°C for 10 minutes, and a 10°C soak.
Two reactions of 50 ml each under 25 ml of mineral oil were
performed.
Amplification products were purified by gel electro-
phoresis in 1% agarose (FMC corporation) in TAE buffer
[14] followed by extraction with the Wizard PCR prep kit
(Promega, Madison WI, USA). 400 ng of product was
subjected to cycle sequencing using the PST-RR Dye
Terminator mix (#402124) supplied by Perkin-Elmer. Se-
quencing primers (59-.39) were BW106 (CCT GTG TCG
GGC CGT GAA GTA), BW102 (GTG GCC AAG ACT
GTG AGG ATG), BW107(CCA ATG AAG ACG TGT
ATG GGT), BW213 (CCA GGG TAG GTG CCA CGA
ACA) and occasionally BW100 (TGC TCC TCA GGC
AGA GGC TGA).
Sequence electropherograms obtained on a model 373 or
377 automated sequencer (Applied Biosystems) were visu-
ally confirmed using Factura software (Applied Biosys-
tems) and then compared with wild-type sequence using
the GeneWorks sequencing project software (Oxford Mo-
lecular).
DNA sequence numbering is according to GenBank
accession number U04357, the genomic AVPR2 sequence
[13]. Note that the original sequence has one error, a
missing T at position 144 in intron A. The GenBank entry
has been corrected.
Cloning and expressing mutant genes
The entire AVPR2 gene was amplified by PCR from
genomic DNA using Pfu (or, rarely, Taq) polymerase and
the manufacturer’s buffer (Stratagene or Perkin-Elmer).
The amplification primers were BW216 (aag gta cCT GAG
TCC GCA CAT CAC CTC C) and BW217 (tgg agc tcA
GGG ATT AGA AAG GCG GAG ACA). Bases in lower
case were added to create KpnI and SacI restriction sites.
The amplification parameters were as above, except that
four 25 ml reactions with 125 ng of DNA template each
were employed.
Amplification products were gel purified and extracted as
above, digested with restriction endonucleases SacI and
KpnI (Pharmacia), and subcloned into the plasmid vector
pCD/PS [15].
cAMP response assay
JEG3 human choriocarcinoma cells (American Type
Culture Collection) were plated in 24-well dishes at 4.8 3
104 or 2.4 3 104 cells/well one to two days, respectively,
prior to transfection and cultured in Dulbecco’s modified
Eagle medium (DMEM) plus 10% Fetal Clone III (Hy-
clone) supplemented with penicillin/streptomycin (10 U/ml,
Sigma), L-glutamine (2 mM, Life Technologies) and 0.1 mM
non-essential amino acids (Life Technologies).
Cells were transfected using calcium phosphate precipi-
tation [16] when cell density reached 70% confluency.
Culture media was replaced with 0.25 ml transfection
media [DMEM plus 0.5% bovine serum albumen, fraction
V (Sigma), supplemented as above] and equilibrated. Each
well then received 10 ng of plasmid expressing the wild-type
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or mutant receptor, 15 ng of the alpha-inhibin-luciferase
reporter plasmid [17], which is cAMP responsive, and 40 ng
of a constitutively active b-galactosidase reporter plasmid
[18] to control for transfection efficiency, with pCD/PS to a
total of 250 mg plasmid as 25 ml of CaPO4 precipitate
suspension. Twenty-four hours after transfection, media
was replaced with transfection media containing no addi-
tions, AVP (Sigma) at varying concentrations, DDAVP
(Sigma) at 10 nM, or forskolin (Sigma) in ethanol at 10 mM.
Each condition was performed in triplicate.
Two and a half hours after stimulation, wells were
aspirated and the cells were lysed in 100 ml/well of 1 X
Reporter Lysis Buffer (Promega), shaken for 10 minutes at
room temperature, then frozen at 280°C. The thawed
lysates were harvested and centrifuged at 3,000 3 g at 4°C
for 10 minutes.
Luciferase activity was measured in 20 ml of lysate
supernate in a Berthold 953 Autolumat luminometer by
injecting 100 ml of Luciferase assay reagent (Promega) and
integrating over 15 seconds. b-galactosidase activity was
measured colorometrically at 410 nm using a previously
described assay [19].
Luciferase activity was corrected for transfection effi-
ciency by dividing by the associated b-galactosidase activity.
Standard deviations (SDs) were calculated on triplicate
experiments. Data analysis and graph preparation made
use of Microsoft Excel and CricketGraph software.
Sequence alignments
Seventeen amino acid sequences from various species
representing V2Rs, oxytocin receptors, V1a and V1b re-
ceptors, and the related amphibian bladder mesotocin
receptor and teleost isotocin receptor were aligned using
the classical algorithm and manually adjusted in Gene-
Works software (Oxford Molecular). The sequence acces-
sion numbers are: Swissprot: P30518 (V2R_HUMAN),
Q00788 (V2R_RATNORV), P48044 (V2R_BOVIN),
P32307 (V2R_PIG), P32306 (OXYR_PIG), Q28756
(OXYR_SHEEP), P30559 (OXYR_HUMAN), P70536
(OXYR_RAT), P37288 (V1AR_HUMAN), P47901
(V1BR_HUMAN), P48043 (V1AR_SHEEP); PIR: I50130
(ICTCN_WSUCKR); GenBank: D86599 (OXYR-
_MUSSp), U82440 (OXYR_MACAC), X93313 (MSTC-
N_TOAD); EMBL: Z11932 (V2R_RATRAT); and Wildin
et al (unpublished data): V2R_MOUSE. Statistical calcu-
lations of significance were performed by the X2 method
using the Yates correction [20].
RESULTS
We previously reported eleven NDI patients with se-
quence variations in AVPR2 [13]. In this study, we wished
to confirm the high frequency of novel AVPR2 variations
by studying more NDI patients. In addition, we assessed
their causal relationship to the disease by testing the ability
of the altered alleles, particularly those predicting missense
variants, to produce functional receptors when expressed in
cell culture. A significant variation from normal in the
ability to transduce signal in vitro suggests that an AVPR2
variation is actually a disease-causing mutation.
Nephrogenic diabetes insipidus subjects
AVPR2 alleles from 25 unrelated subjects with a clinical
diagnosis of NDI were studied (Table 1). Blood samples
were obtained with informed consent by the subjects’
treating physicians and, in most cases, mailed to the authors
from distant locations. Twenty-three of the subjects were
males, while two were females whose NDI symptoms
required medical attention. All these patients had clinical
evidence of a defect in urine concentrating ability that was
resistant to parenteral infusion of vasopressin, or desmo-
pressin (DDAVP), or such evidence existed for a first or
second degree affected male relative. The available data
from clinical records reporting the diagnostic studies for
patients whose mutations were analyzed for function are
shown in Table 2.
There was no prior affected male in the families of 13 of
the 23 patients for whom family history was available. We
defined these as sporadic cases because they occurred
without prior knowledge of clinical disease in the family.
Genetic counseling is challenging in such cases because
they may, in reality, represent inherited X-linked muta-
tions, new mutations in AVPR2 not present in the patient’s
parents, autosomal recessive AQP2 mutations, cases of
non-genetic NDI, or other disorders having NDI as a
feature. In four of the 13 sporadic cases in our cohort, the
patient’s mother, and sometimes other female relatives,
had subclinical complaints of polyuria and polydipsia. The
age at definitive diagnosis ranged from two weeks to eight
years, with the majority diagnosed within the first four
months of life. The racial backgrounds of the subjects
included Caucasian/northern European (N 5 13), East
Indian (N 5 1), African (N 5 1), Okinawa (N 5 1), Latino
(N 5 2), and unknown (N 5 7).
AVPR2 variations in nephrogenic diabetes insipidus
patients
The genomic DNA sequence of AVPR2 was completely
determined for each patient by direct sequencing of PCR
product. Differences from the published reference se-
quence were called “variations,” and the alleles in which
they were found termed “variant,” because their effect on
the function of the encoded V2 receptor was not immedi-
ately known. Variants whose function is indistinguishable
from the reference wild-type allele are properly termed
polymorphisms, while those associated with measurable
differences may ultimately be denoted mutant. Twenty-four
different variant alleles of AVPR2 were present among the
25 study subjects (Table 1). Two patients who were not
known to be related harbored the same variation. Several
had variations reported in previous NDI studies (Table 1,
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column 8), including one (S167L) from our prior study [13].
The two female subjects were each heterozygous for small
deletions that were easily detected in the sequence electro-
pherograms. One additional patient with diabetes insipidus
had no detectable variations in AVPR2. He was excluded
from the cohort reported here because reduced responsive-
ness to vasopressin had not been documented.
In most cases, only a single DNA sequence variation was
found in each mutant allele. Four alleles had two or more
variations (the common silent polymorphism in the codon
for leucine at position 309 was not counted as a variation).
All variant alleles predicted a change in the amino acid
sequence of the AVPR2 polypeptide. Four deletions
(850delG, 766delTG, 838del40, and 1216delG) and one
insertion (1044insC) are predicted to cause frameshifts
with early chain termination and alteration of the carboxy-
terminal peptides. The allele (96-01) harboring one such
deletion also contained a silent change in the first intron, as
well as an amino acid substitution in the codon just
preceding the deletion.
Two single-base substitutions (G1311A, T1473A), one
single-base deletion (1507delG, from a female subject), and
one single-base insertion (874insG) create premature ter-
mination (nonsense) codons. In another allele, a substitu-
tion (G1343A) in the critical 11 position of the splice
donor for the second intron likely results in aberrant
splicing and an altered messenger RNA. The variant allele
from a second female subject (1267del3) revealed an
in-frame, three base-pair deletion predicting the loss of
Valine 278 or 279, but an otherwise normal receptor
protein. The remaining alleles harbored one or two single
base-pair substitutions that predict amino acid substitutions









variations Predicted Consequences to V2R
Previous
observation
96–10 M African 2 maternal uncles 4 months A214G,
C847A,
850delG
Silent in intron A, R139S,
frameshift after R139 and TER
after 21 more codons






96–05 M US Latino None 1 month A595G N55D
96–03
1 3–124







None 22 months A707G Q92R
93–362 M Unknown Unknown Unknown 766delTG Frameshift after L111 and TER
after 78 more condons
93–397 M US Caucasian 2 maternal uncles Unknown C769T R113W [36, 37, 39]
96–06 M GB Unknown Maternal 2nd cousin 3 months G796C G122R
93–530 M US Caucasian None 2 months 838del40 Deletion of 13 residues with
frameshift after L135 and TER
after 12 codons
97–01 M US Hawaiian
(Okinawa)
Extensive 3 months 874insG Y148X
96–01 M Unknown Maternal half-brother 2 weeks C932T S167L [13, 36, 37, 42]
96–04 M US Caucasian
(N. European)







972888 M US Caucasian Mother symptomatic 4 months 1044insC Frameshift after T204, TER after
53 more codons
96–02 M US Unknown Mother, 2 sisters
symptomatic
3 weeks T1088C L219P [43]




97–11 M US Latino None 5 months T1247A M272K
972462 F US Unknown None 4 years 1267del3 DV279 [41, 44]
97–13 M US Caucasian None 6 months G1311A W293X [36] (different base,
same
consequence)
971838 M US Caucasian
(Ireland)
2 maternal uncles and
one male cousin
16 weeks G1343A Disrupts 59 spice signal for intron
B (AAGgtggg3 AAGatggg)
971819 M US Caucasian Extensive 2 weeks T1473A L312X [36, 45]
97–09 M US Caucasian
(English)
Mother symptomatic 4 months C1483A S315R
95–13 M US Unknown None 9 months C1489A N317K




97–28 F US Caucasian
(German)
Father and 2 paternal
half-uncles
1 year 1507delG W323X
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(missense) only. Two alleles had two changes each: 972121
with G12E and C319R substitutions, and 96-04 with R181C
and V215M substitutions. If a conservative amino acid
substitution is defined as one resulting in no net electrical
charge and no change in the polarity of a neutral residue,
then four of the non-polymorphic missense variations ob-
served predict conservative changes (L81F, V215M, L219P,
N321Y) and ten predict non-conservative changes.
Functional characteristics of AVPR2 mutations
Theoretically, some AVPR2 sequence variations may not
cause any change in the function of the encoded receptor,
although they are found in patients with a clinical diagnosis
of NDI. They represent polymorphisms, or normal varia-
tions that may be found in individuals not affected with
NDI, or even in an individual affected with NDI that is due
to mutations in another gene, like AQP-2.
From a clinical genetics perspective it is therefore valu-
able to establish whether or not an AVPR2 gene sequence
variation from an NDI patient indeed results in a loss of
receptor function. This is particularly important in cases of
NDI without a strong X-linked family history. Defining the
functional capacity of variant receptors is likewise essential
for the scientific analysis of the structure-function relation-
ship of the seven-transmembrane-domain protein.
To test the function of the putative mutant receptors, we
cloned the subject’s AVPR2 gene into an expression plas-
mid, transfected it into a V2 receptor-negative human
tumor cell line, and tested the ability of the transfected cells
to respond to AVP via the experimentally expressed recep-
tors. Since the subjects’ genes were cloned using PCR,
which can result in the introduction of base change arti-
facts, we used a high-fidelity polymerase. The sequence of
each cloned insert was then determined to verify its identity
to that obtained directly from the subject’s independently
amplified PCR product. We chose to test the missense
variations, because they are much more likely to represent
masquerading polymorphisms than those changes predict-
ing protein truncation. We included two from the latter
category (one nonsense and one frameshift) in our selec-
tion as negative controls.
The transfected cells’ ability to respond to AVP via the
V2 receptors was measured in an assay previously used to
assess G protein signaling pathways coupled to the adren-
ergic and muscarinic receptors [21]. A plasmid bearing a
cAMP-responsive promoter driving a luciferase reporter
gene is co-transfected into the cells with the V2 receptor
expression plasmid. Physiologic increases in cAMP due to
agonist-induced activation of the expressed V2R are re-
flected in increased luciferase transcription, translation,
and enzymatic activity. This occurs because elevations of




change Urine concentration defect
96–08 N321Y 4 hour water deprivation test: maximum serum/urine Osma 305/30, followed by 0.4 mg intramuscular DDAVP 3
serum/urine Osm 311/53, with no subsequent response to high dose DDAVP. Results confirmed at 4 years of age
following trial of intranasal DDAVP up to 20 mg/dose.
97–13 W293X Presenting serum sodium 158 mEq/liter. “He did not respond to subcutaneous injection of ADH”
93–397 R113W No testing records; family history of X-linked disease
3–124 L81F Short stature, FTTb; Pitressin challenge - urine Osm, “responded somewhat”
96–03 L81F Testing records not available; sporadic
96–02 L219P Spontaneous serum/urine Osm 323/19; after 0.2 mg subcutaneous DDAVP minimum serum Osm 324, maximum urine Osm
106
96–06 G122R No testing records; family history of X-linked disease
88–082 Y205C No testing records; family history of X-linked disease
87–151 W323R No testing records; family history of X-linked disease
93–530 D136fs No testing records; family history of X-linked disease; hospitalized 14 times by age 2.5 years for hypernatremic dehydration
93–169 S167L Spontaneous serum/urine Osm 360/179; “No response” to 0.05, 0.1 or 0.2 cc intranasal DDAVP, maximal urine Osm 196
96–01 S167L No testing records; maternal half-brother is affected
92–233 P95L No testing records; adopted
95–13 N317K Spontaneous serum/urine Osm 317/131; urine before/after subcutaneous DDAVP: output 5 5.5/4.6 cc/kg/hr, maximum Osm
109/108
96–05 N55D Presenting serum sodium 156 mEq/liter; vasopressin challenge: 0.115 mg up to 5 mg gave “no response”
93–141 L53R No testing records; has younger affected sister
97–09 S315R Water deprivation test: dehydrated to 96% body weight, serum/urine Osm 330/173; DDAVP challenge 20 mg intranasal 3
“no response”, then 2 mg intravenous 3 “no response.” ADH level . 40 pg/ml
97–11 M272K Presenting serum sodium 161 mEq/liter serum/urine Osm 352/111, later 367/153; no decrease in urine output after 0.01 mg
intranasal DDAVP or after 1 Unit subcutaneous Pitressin, urine specific gravity remained below 1.005
96–04 R181C 1
V215M
Spontaneous serum/urine Osm 327/88; “he did not respond to [a vasopressin stimulation test] in the hospital”
972121 G12E 1
C319R
Adopted. Presenting serum sodium 161 mEq/liter serum/urine Osm 335/126, later 323/151; urine Osm 142 (unchanged) after
5 mg intranasal DDAVP, maximum of 158 one hour after parenteral aqueous pitressin
a Osm is osmolality, mOsm/kg
b FTT, failure to thrive
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cAMP activate protein kinase A (PKA), which phosphory-
lates a transcription factor (CREB), in turn resulting in the
activation of transcription at gene promoters bearing
CREB binding sites, such as the a-inhibin promoter in the
luciferase plasmid. Since activation of PKA is felt to be
involved in the fusion of aquaporin-2-laden vesicles with
the apical membrane of the collecting duct epithelium in
response to AVP stimulation, this downstream readout
mimics the events occurring with activation of the V2
receptor in vivo. Furthermore, the wild-type receptor in this
assay responds to concentrations of AVP that cause water
conservation in normal individuals (Fig. 1).
Because the transfection efficiency may vary between
different wells in the same experiment, a third plasmid with
a constitutively active b-galactosidase gene is also included
in the transfection. Luciferase activity in the cell lysates is
then divided by the b-galactosidase activity to correct for
transfection efficiency. The assay is extremely sensitive, it
reflects a physiologic signaling cascade, and it does not
depend on artificial elevation of cAMP levels by pharma-
cological inhibition of phosphodiesterase.
Eighteen variant AVPR2 alleles from NDI patients, two
identical wild-type alleles from different subjects (wt and
wt2), and one allele with three mutations generated by
PCR error (M1V 1 G185S 1 I221T) were tested in this
fashion (Fig. 1). All NDI alleles demonstrated a substan-
tially decreased ability of the altered receptor to activate
the luciferase reporter in response to AVP. Twelve clearly
had no response to AVP at concentrations as high as 320
nM, 105-fold higher than the lowest concentration tested,
where the wild-type receptor had clearly detectable activity.
Six of the NDI alleles (N321Y, R113W, L81F, P95L,
N317K, and R181C/V215M) showed partial or complete
responses at AVP concentrations from 1.5 logs to four logs
higher than required for the wild-type. The second wild-
type allele, wt2, the normal allele from a heterozygous
female, responded to AVP in a manner identical to the
first.
The allele bearing the three PCR-generated mutations
(M1V, G185S, and I221T) demonstrated nearly normal
function in this assay. The level of signal obtained at the
three lowest AVP concentrations tested was significantly
lower for this allele than for wild-type, yet it was measur-
able and therefore greater than those of the patient derived
alleles.
In order to confirm that the luciferase activity observed
was due to activation of the V2 receptor derived from the
transfected genes, and to search for major mutation-related
changes in agonist discrimination, the cells were stimulated
in parallel with 10 nM desmopressin (dDAVP), a V2-
selective agonist (Fig. 1, right side). In all cases, the level of
corrected luciferase activity stimulated by 10 nM dDAVP
was similar to that induced by 10 nM AVP.
The diterpene forskolin stimulates adenylyl cyclase inde-
pendent of G protein signaling. Parallel stimulation of the
V2 receptor-expressing cells with 10 mM forskolin demon-
strated that the reporter system was intact in each experi-
ment, and that the level of maximal stimulation by the
wild-type receptor was similar to that induced by receptor-
independent mechanisms (Fig. 1, right side).
Increasing the amount of reporter plasmid transfected
increased the overall level of luciferase activity, but it did
not change the concentration at which the maximal lucif-
erase activity was first reached (not shown). This suggests
that the rate-limiting step responsible for the plateau in the
signaling response at AVP concentrations above 0.032 nM
in wild-type resides in the signaling pathway upstream of
luciferase transcription activation. Control cells that were
not transfected did not have detectable luciferase activity.
Cells receiving the luciferase and b-galactosidase reporter
plasmids plus the pCD/PS expression plasmid without a V2
receptor gene insert had basal luciferase activity similar to
the fully transfected, but unstimulated cells (not shown).
The experimental results obtained from this assay were
reproducible on different occasions.
Amino acid conservation in related receptors
Conservation of amino acid residues over long periods of
evolution is an acceptable predictor of structural or func-
tional importance. Members of the vasopressin/oxytocin
receptor subfamily are found broadly in vertebrate species,
including amphibians and fishes. Comparing their se-
quences provides a means to query which amino acid
residues may be most important in the overall function of
the receptors. Since they all bind quite similar natural
ligands, their comparison over wide evolutionary distances
is more meaningful than a comparison with other G
protein-coupled receptors that have very different natural
agonists, and thus have had different evolutionary con-
straints.
We extracted from the public databases protein se-
quences whose level of similarity to the human V2R was
significant, as defined by the XrefDB algorithm [22], and
aligned their amino acid sequences. Seventeen sequences
were used (Fig. 2). They included type 2 vasopressin
receptors from six mammals, oxytocin receptors from six
mammals, type 1a vasopressin receptors (V1a) from two
mammals, type 1b vasopressin receptor from human (V1b),
and two more distant relatives: the isotocin receptor from
the White Suckerfish and the mesotocin receptor from the
Black Toad.
Eighty-five residues, excluding the initiating methionine,
were completely conserved among the seventeen receptors,
suggesting that they may play a role in ligand binding, in
establishing the necessary secondary or tertiary structure,
or in transmitting an activation signal to G proteins. The
preponderance of wholly conserved residues lies in the
transmembrane domains and in the first and second extra-
cellular loops. The palmitoylation site (CC) and the more
broadly conserved domain in the seventh transmembrane
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Fig. 1. V2 receptor arginine vasopressin (AVP) dose response. Each pair of panels represents a single set of triplicate experiments, and each data point
and associated bar represent the mean and SD, respectively. The horizontal axis of the left panels is marked in half-log increments of AVP concentration.
The vertical axis is expressed as Luciferase activity (in arbitrary light units) divided by b-galactosidase activity (in arbitrary absorbance units). The data
are normalized to wild-type activity to facilitate comparison between panels. The baseline wild-type activity is defined as zero and the maximum mean
wild-type activity for each panel is defined as 100%. Variants shown here but not listed in Table 1 were previously reported [13].
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Fig. 1. Continued
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segment are also among the completely conserved sites. In
other G protein receptors, the cytoplasmic loops are exper-
imentally implicated in receptor:G protein interactions
[12]. Since members of this collection couple to different G
protein subsets, it is not surprising that residues in the
cytoplasmic loops are commonly different. Close inspection
reveals a high level of conservation in some cytoplasmic
domains among receptors that signal via a similar G protein
subset.
Inspection of Figure 2 also suggests that completely
conserved residues are disproportionately represented
among the missense mutations associated with NDI. The 85
completely conserved residues are mutated 24 times (28%),
whereas the remaining 286 residues not completely con-
served were altered only 24 times (8.4%). The association is
statistically significant (X2 with Yates correction 5 21.2,
p , 0.001).
DISCUSSION
Genetic variation causes human disease when it changes
the expression of a gene or the function of its protein
product. New variations in the AVPR2 gene encoding the
V2 vasopressin receptor are thus strongly implicated in the
causation of congenital nephrogenic diabetes insipidus.
Nevertheless, variations without functional significance, or
polymorphisms, have been reported. Identifying variations
in AVPR2 in NDI patients and confirming their functional
significance are important for both accurate genetic coun-
seling and for advancing scientific understanding of G
protein-coupled receptors.
In this report, we describe a large cohort of independent-
ly-ascertained NDI patients, including two females, each of
whom has one or more genetic sequence variation in
AVPR2. Fifteen of the alleles have not been previously
reported. Altogether, over 80 different variant AVPR2
alleles have been associated with NDI. The large number of
novel mutations is consistent with an X-linked recessive
disorder with reduced genetic fitness, and it presents a
challenge for clinical DNA diagnosis.
Sporadic cases
Between this study and our previous report [13], 52% of
the subjects represented sporadic cases, each with a novel
AVPR2 variation. This diversity is further evidence against
the once widely accepted, and now disproved, “Hopewell
hypothesis” that all NDI patients in North America derived
from a single founder family [23, 24].
Since each of these sporadic cases was shown to have a
mutation in AVPR2, it is possible that their mothers, and
potentially other female relatives, are unwitting carriers of
NDI. Such carriers have a recurrence risk of 50% for NDI
in subsequent male births.
For X-linked disorders with a genetic fitness of zero in
males, like Duchenne muscular dystrophy, the proportion
of sporadic cases where the mother of the patient is a
carrier of the disease allele is two thirds. It is reasonable to
assume that the likelihood of reproduction in males with
NDI was limited in past generations, and may still be in
medically under-served regions.
Invoking Haldane’s Indirect Method, this suggests that at
least two thirds of mothers of sporadic NDI cases may be
carriers [25]. We conclude that mothers of sporadic males
with NDI due to a mutation in AVPR2 are at substantial
risk of being carriers of a disease-causing allele, and carrier
testing should be made available. Successful testing has
been done on an experimental basis [13, 26].
Equally important, locus heterogeneity for NDI clearly
exists in the form of autosomal mutations in aquaporin-2
(AQP2). Thus, these sporadic patients cannot be assumed
to harbor NDI-causing AVPR2 mutations, and any AVPR2
sequence variations found in them, especially those predict-
ing a missense only, must initially be suspect. This is
particularly important if the presence of the mutation is to
be used as evidence of X-linked inheritance in genetic
counseling. Furthermore, the functional incapacity of the
variant molecule must be clearly established if NDI-asso-
ciated variations are to be used to draw inference about the
structure-function relationship of the V2 receptor.
All patients in this study demonstrated variations in the
AVPR2 gene. The nonsense and frameshift changes are
reasonably assumed to be mutations that eliminate recep-
tor function; this was confirmed by testing one of each (Fig.
1; D136fs and W293X). All but one of the missense
variations were tested and were shown to affect the func-
tion of the V2 receptor (Q92R was not tested). Therefore,
it is highly unlikely that any of these patients have NDI
solely as a result of defects in aquaporin-2, the action of
which is downstream of receptor signaling. This supports a
conclusion that the incidence of autosomal recessive NDI is
quite low in the sampled population relative to X-linked
NDI, even when families with a history of NDI in prior
generations are excluded. On the other hand, when con-
sanguinity among the parents is present, or when the
proband is a girl, mutations in AQP-2 should be more
strongly considered. Vargas-Pousou et al found ten of
twelve families with NDI to have AVPR2 variations; the
other two had autosomal recessive aquaporin-2 defects
[11]. In one of the autosomal recessive cases the parents
were first cousins, and in the other case the proband was a
girl. Females who are heterozygous for an inactivating
AVPR2 allele may show clinical disease as a result of
skewed X-inactivation [27, 28].
Signaling capacity among variant receptors
Non-functional alleles. An allele with a frame shift at
residue 136 and one with a nonsense mutation at residue
293 gave no response in our sensitive assay of receptor
function, as expected. The majority of the missense muta-
tions also failed to signal when stimulated with AVP. The
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N55D variation alters a residue that is universally con-
served among more than 150 representative G protein-
coupled receptors (http://mgddk1.niddk.nih.gov:8000/com-
prehensive.html) [29], suggesting it is not only important
for the vasopressin/oxytocin family, but is essential for all G
protein-coupled receptors. It also inserts a charged residue
in the middle of a transmembrane domain. The L53R,
G122R, M272K, S315R, C319R, and W323R variations
(and the untested Q92R) each place a charged residue in a
transmembrane domain, and may thereby disrupt proper
assembly of the receptor.
Substitution of serine by leucine at residue 167 also
eliminates signaling in our assay. Previously, Oksche et al
showed that adenylate cyclase stimulation by the S167L
variant is absent along with a total lack of cell surface AVP
binding [9]. Immunoblot analysis indicated lack of post-
translational processing and probably increased degrada-
tion, supporting a conclusion that the nascent protein is not
properly targeted to the plasma membrane. The reason
why a non-polar substitution for this nucleophile in the
middle of the fourth transmembrane domain prevents
receptor assembly remains unknown.
The substitution of proline for leucine at position 219 in
the fifth transmembrane domain likely kinks an important
a helix and may disrupt protein targeting as well, account-
ing for its lack of activity. Lastly, cysteine in place of
tyrosine at position 205 in the C-terminal end of the second
extracellular loop, previously analyzed by Yokoyama et al
[30], is apparently present at the cell surface. It has a
reduced affinity for AVP and fails to significantly stimulate
cAMP accumulation, even at high concentrations of ago-
nist, which is consistent with our observations. Disruption
of protein folding by promiscuous inter- or intra-molecular
disulfide bonding is one explanation for the reduced func-
tion of similar receptors with mutations that introduce new
cysteines. Alternatively, data from the cognate mutation
(F189C) in the dopamine D2 receptor suggest that this
residue may be implicated in the formation of an active
ligand binding crevice [31].
Alleles with partial activity. Six of the alleles with missense
variations (L81F, P95L, R113W, R181C 1 V215M, N317K,
and N321Y) retained some capacity to signal in response to
AVP and dDAVP, albeit at substantially higher concentra-
tions of ligand. The L81F mutation was detected in each of
two geographically separated families, but this does not
necessarily indicate a recurrent mutation. The first patient,
3-124, was described as having a partial response to vaso-
pressin challenge when he was diagnosed at age eight
(Table 2). His two nephews with the same allele have
reportedly had a variable disease course, suggesting that
partial receptor activity in vitro phenotype may correlate
with a milder clinical phenotype. Leucine is nearly invariant
at this position among more than 150 G protein-coupled
receptors [29], being replaced only rarely with methionine
or threonine. The hydrophobic nature of phenylalanine
may be tolerated in this second transmembrane domain,
but the larger aromatic ring may displace the helix suffi-
ciently to partially impair ligand binding or G protein-
coupling.
The P95L mutation at the extracellular end of the second
transmembrane domain showed a small response to very
high concentrations of AVP, concentrations much higher
than one would expect to find in vivo. It seems unlikely that
this poor response is distinguishable from no response in
vivo. Since leucine is seen at this position in a number of
other G protein-coupled receptors (dopamine D4, melato-
nin, some 5HT receptors, muscarinic receptors) [29], this
change may not disrupt overall receptor structure, but
rather alter part of an important ligand binding domain.
Indeed, Kojro et al showed that P95 is within a V2 receptor
segment that contacts AVP in photoaffinity labeling exper-
iments [32].
The function of the R113W mutation has been tested in
cell lines by Birnbaumber, Gilbert and Rosenthal [33].
They found a normal abundance of binding sites, but a
reduced kD of approximately 100 nM versus 5.3 nM for the
wild-type receptor. The EC50 of adenylyl cyclase activity in
cell homogenates was 25- to 60-fold higher for the mutant
receptor than for the wild-type. Our data, obtained in intact
cells, demonstrate a shift in the concentration of AVP
required for equivalent signaling of approximately 60-fold,
entirely consistent with the previous results.
The substitution of tryptophan for arginine could con-
ceivably alter agonist binding affinity by eliminating a
charge. Supporting this model, arginine 113 was also
present in one of the AVP-photoaffinity-bound peptides
identified by Kojro et al [32]. Alternatively, the less flexible
tryptophan side chain might stearically inhibit a required
disulfide bond formation between the adjacent cysteine 112
and cysteine 192 in the second extracellular loop. Work
with b-adrenergic receptors has shown a preponderance of
very low affinity binding sites in mutants where either
cysteine in this bond is substituted with valine [34].
This allele retains the most function of all those tested
from NDI patients. Sufficient clinical information is not
currently available in our case to distinguish the disease
course from that found with other mutations. Systematic
Fig. 2. Amino acid alignment of V2 receptor-like sequences. Putative
transmembrane segments are underlined. Completely conserved residues
are noted below the alignment. Known non-polymorphic missense varia-
tions associated with NDI are identified above the alignment. Variations
from this paper are in bold, while previously reported ones are in plain
font (L43P,G107E [11]; L44F, L62P, D85N, T204N,V206D [37]; L44P,
S167T [46]; L53R, L83P, P95L, S167L, W323R [13]; R64W, V88M,
R106C, C112R, S126F, A147V, W164S, A285P [36]; H90R [47]; R113W
[48]; Y128S, R181C, P286R [3]; A132D, R137H [4]; R143P [49]; G185C,
R202C, Y205C [5]; T207N, L219P [43]; V277A, Y280C, L292P [39];
P286L [44]; L309P [50]; P322S, P322H [51]; L219R [28]). Missense
changes found cis to another missense variation are underlined. See
Methods for sequence names and accession numbers.
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testing of such individuals is clearly desirable, but it has
thus far proven impractical.
The N317K and N321Y mutations have not been previ-
ously reported, but also retain some signaling capacity.
Surprisingly, these mutations, as well as L81F, P95L, and
R113W, which retain function, occur in residues that are
completely identical across the receptor subtypes (Fig. 2).
This suggests that a minimum threshold of activity is
required for evolutionary conservation at these positions,
and that any substitution likely reduces activity below the
threshold. These residues may thus be important contact
points in ligand recognition or in G protein activation.
An identical mutation to N317K at the cognate position
in the hamster b-adrenergic receptor (N318K) has previ-
ously been analyzed. Agonist binding affinity was reduced
about tenfold, whereas antagonist binding was similar to
wild-type [35]. On the basis of limited maximal stimulation
of adenylate cyclase, the authors later concluded that the
mutation also created a partial defect in G protein coupling
[34]. A similar coupling defect is therefore hypothesized for
both N317K and N321Y in the V2 receptor.
Clinical data from the diagnostic studies of subjects
whose V2 receptor variants were tested (Table 2) did not
reveal differences in urine concentrating ability that could
be correlated with the degree of receptor activity witnessed
in vitro.
Alleles with two missense mutations. The R181C variation
was found in the same allele as a novel variation, V215 M.
R181C has been reported three other times in NDI patients
[3, 36, 37], once in association with a three-residue deletion
elsewhere in the same allele [3]. Experimental analysis of
the two mutations separately indicated that R181C reduced
receptor function but that the three-codon deletion did not
[38]. Thus, it is likely that the R181C variation is a
disease-causing change in our patient as well. Distraction of
the normal disulfide bonding between cysteines in extracel-
lular loops I and II has previously been suggested as a basis
for the observed loss of function observed in the R181C
allele [3].
In our patient, this change may have occurred on the
background of the V215M variation representing a rare
polymorphism. Alternatively, the V215M change could
contribute to reduced receptor function. Interestingly, the
same conservative substitution (V 3 M) occurring at a
different position (residue 88) but in a similar transmem-
brane-segment context was reported by Pan et al to repre-
sent a polymorphism on genetic grounds [3]. Hence,
V215M may represent another rare polymorphism, but this
must be confirmed by independent functional analysis.
Two variants, G12E and C319R, were identified in
another patient. The G12E change has been reported
previously in an allele with a different downstream mis-
sense mutation (L292P) in an NDI patient [39]. Wenkert et
al later demonstrated normal function of a synthetic allele
with only the G12E change and absent function in an
isolated L292P allele [40], suggesting that G12E is a
polymorphism. Schoneberg et al confirmed the loss of
receptor function caused by L292P [41]. Our tentative
conclusion that C319R is responsible for the loss of recep-
tor function should be confirmed by expressing it indepen-
dently.
One allele in this study was obtained experimentally, not
from an NDI patient. It has three different mutations in the
coding region, M1V, G185S, and I221T. Its near-normal
function seems initially surprising since the presumed ini-
tiation codon is eliminated, and another mutation at resi-
due 185, G185C, has been reported in NDI [5]. Further-
more, I221T is a non-conservative, non-polar-to-polar
change. However, a methionine is also encoded by codon 3,
presumably allowing for translation initiation there. Rela-
tively normal function of this receptor suggests that the first
two amino acids of the putative coding sequence may not
be very important for receptor function and that codon 3
can function as the initiator.
Secondly, serine at position 185, in the second extracel-
lular loop, is probably less disruptive than cysteine at the
same position. As discussed above, the cysteine at position
192 is believed to form a disulfide bond with C112, so a new
cysteine at position 185 probably competes with C192 for
inter-loop disulfide bond formation, disrupting secondary
structure. A new serine at this position is unlikely to have
such an effect.
Threonine in place of isoleucine at position 221, the
middle of the fifth transmembrane domain, involves a
change in polarity, but not in size. This third mutation may
affect receptor function little because it is well tolerated in
the transmembrane domain.
Correlates from sequence comparisons
Clustering of disease-associated variations is frequently
ascribed to mutation “hot spots.” While a few mutations
clearly recur, our analysis of the reported AVPR2 missense
mutations in NDI supports a strong bias for mutations in
highly conserved residues of the protein. This suggests that
among all randomly occurring mutations in this gene, those
that markedly disrupt receptor function cause clinically
recognized disease.
Correspondingly, persons with mutations that change
other, less well-conserved residues and have a milder effect
on receptor function probably exist in the population. They
may only present clinically when challenged with extreme
water deprivation and they probably escape formal diagno-
sis. Alternatively, the kidney may possess a secondary
means of water conservation that masks the effects of
functionally mild mutations in AVPR2.
Conclusions
The documentation of a high frequency of sporadic cases
and the demonstration of further allelic heterogeneity
provided in this study have immediate implications for the
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diagnosis and genetic counseling of patients with congenital
NDI and their families. AVPR2 mutation detection and in
vitro confirmation of the functional significance of muta-
tions are clearly valuable techniques that should be clini-
cally available, especially for the relatively common spo-
radic cases.
From a structure-function standpoint, these data support
some preliminary generalizations about the V2 receptor.
First, mutations occurring in receptor domains known to be
involved in binding AVP tend to produce partial signaling
deficiencies. Second, those that alter transmembrane do-
mains by inserting a charged residue tend to lack receptor
function regardless of the ligand concentration provided,
presumably because they are either improperly assembled
or fail to reach the cell surface. Third, mutations with only
slight effects on V2 receptor function are generally not
found among patients with clinically significant NDI. Fur-
ther dissection of the structural and functional deficits of
the mutant V2 receptors will yield valuable insights into the
underlying mechanisms of G protein-coupled receptor
function.
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